Pharmaceutical Industry Reports plasminogen activator inhibitor market | Page 2

REPORT DESCRIPTION
Plasminogen Activator Inhibitor Market – Overview
Plasminogen activator inhibitors also known as Serpin E1 is a protein present in the body whose elevated levels
are responsible for thrombosis and atherosclerosis. (Plasminogen Activator Inhibitor Type 1 (PAI-1) is mainly
secreted by the endothelium (cells lining blood vessels), and adipose tissues whereas Plasminogen Activator
Inhibitor Type 2 (PAI-2) is secreted by the placenta and only present in significant amounts during pregnancy.
PAI-1 plays an important role in aging and is secreted in senescent cells. Complete plasminogen activator
inhibitor 1 deficiency (complete PAI-1 deficiency) is a disorder that causes abnormal bleeding.
Increasing number of pipeline drugs for treating wounds and thrombosis can propel the growth of plasminogen
activator inhibitor market. For instance, Denver Health and Hospital Authority is undergoing clinical phase II
study for treating thromboembolism and wounds by aspirin and rosuvastatin. The study aims to measure PAI-1
and tissue plasminogen activator inhibitor levels in the plasma after drug treatment. The study started in February
2017 and is estimated to complete in December 2021.